Payment overview · 2025
General Payments
$316.64
17 reported records · 13 companies
Healthcare provider profile · identity verified
Rhonda Lynne Sharp, AGPCNP-BC
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner|Adult Health · DALLAS, TX · NPI 1407241714
Verified facts
What the public records show
CMS Open Payments records show Rhonda Lynne Sharp, AGPCNP-BC received $316.64 in general payments during 2025 across 17 reported records.
PFIZER INC. accounted for 22.3% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 21 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 40 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 25 claims for Symbicort by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 159 claims for Jardiance by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 81 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 26 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Eliquis by this doctor in 2024.
SANOFI-AVENTIS U.S. LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LANTUS as an associated drug or biological on 12 records involving 11 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Lantus by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| PFIZER INC. | Unresolved — no canonical attribution shown | $70.64 | 22.3% | 3 | 2025 |
| ACADIA Pharmaceuticals Inc | Unresolved — no canonical attribution shown | $35.36 | 11.2% | 2 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $33.01 | 10.4% | 2 | 2025 |
| Corcept Therapeutics | Unresolved — no canonical attribution shown | $24.33 | 7.7% | 1 | 2025 |
| Azurity Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $22.43 | 7.1% | 1 | 2025 |
| SANOFI PASTEUR INC. | Unresolved — no canonical attribution shown | $19.79 | 6.2% | 1 | 2025 |
| Cranial Technologies, Inc | Unresolved — no canonical attribution shown | $18.95 | 6.0% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $17.50 | 5.5% | 1 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $15.95 | 5.0% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $15.94 | 5.0% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $15.37 | 4.8% | 1 | 2025 |
| SANOFI-AVENTIS U.S. LLC | Unresolved — no canonical attribution shown | $13.71 | 4.3% | 1 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $13.66 | 4.3% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $316.64 | 17 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $70.64 | 3 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $70.64 | 3 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $45.41 | 2 | 2025 |
Source payment records
|
|||||
| DAYBUE Normalized: daybue |
Drug | ACADIA Pharmaceuticals Inc | $35.36 | 2 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $33.01 | 2 | 2025 |
Source payment records
|
|||||
| PENBRAYA Normalized: penbraya |
Biological | PFIZER INC. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| TRUMENBA Normalized: trumenba |
Biological | PFIZER INC. | $25.23 | 1 | 2025 |
Source payment records
|
|||||
| Korlym Normalized: korlym |
Drug | Corcept Therapeutics | $24.33 | 1 | 2025 |
Source payment records
|
|||||
| EDARBI Normalized: edarbi |
Drug | Azurity Pharmaceuticals, Inc. | $22.43 | 1 | 2025 |
Source payment records
|
|||||
| BEYFORTUS Normalized: beyfortus |
Biological | SANOFI PASTEUR INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| FLUZONE QUADRIVALENT NORTHERN HEMISPHERE Normalized: fluzone quadrivalent northern hemisphere |
Biological | SANOFI PASTEUR INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| MENQUADFI Normalized: menquadfi |
Biological | SANOFI PASTEUR INC. | $19.79 | 1 | 2025 |
Source payment records
|
|||||
| Doc Band Normalized: doc band |
Device | Cranial Technologies, Inc | $18.95 | 1 | 2025 |
Source payment records
|
|||||
| AIRSUPRA Normalized: airsupra |
Drug | AstraZeneca Pharmaceuticals LP | $17.50 | 1 | 2025 |
Source payment records
|
|||||
| Cologuard Collection Kit Normalized: cologuard collection kit |
Device | Exact Sciences Corporation | $15.95 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $15.94 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $15.37 | 1 | 2025 |
Source payment records
|
|||||
| TZIELD Normalized: tzield |
Biological | SANOFI-AVENTIS U.S. LLC | $13.71 | 1 | 2025 |
Source payment records
|
|||||
| CAPVAXIVE Normalized: capvaxive |
Biological | Merck Sharp & Dohme LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| ENFLONSIA Normalized: enflonsia |
Drug | Merck Sharp & Dohme LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
| GARDASIL 9 Normalized: gardasil 9 |
Biological | Merck Sharp & Dohme LLC | $13.66 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 159 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
40 | 12 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
25 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
159 | 51 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
81 | 13 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
26 | 13 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
68 | 20 |
| SANOFI-AVENTIS U.S. LLC Exact reporting entity; no affiliate inference |
2025 | LANTUS open payments reported associated product |
CMS Open Payments — General Payments 12 supporting records · 11 recipient NPIs · example record 1233196856 |
Lantus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 630 | 192 |
| Amlodipine Besylate | Amlodipine Besylate | 448 | 144 |
| Lisinopril | Lisinopril | 342 | 115 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 302 | 98 |
| Metformin Hcl | Metformin Hcl | 272 | 97 |
| Losartan Potassium | Losartan Potassium | 230 | 69 |
| Gabapentin | Gabapentin | 228 | 97 |
| Pantoprazole Sodium | Pantoprazole Sodium | 198 | 67 |
| Hydrochlorothiazide | Hydrochlorothiazide | 175 | 58 |
| Carvedilol | Carvedilol | 167 | 52 |
| Ibuprofen | Ibuprofen | 163 | 79 |
| Jardiance | Empagliflozin | 159 | 51 |
| Trazodone Hcl | Trazodone Hcl | 142 | 48 |
| Celecoxib | Celecoxib | 137 | 41 |
| Levothyroxine Sodium | Levothyroxine Sodium | 135 | 41 |
| Omeprazole | Omeprazole | 128 | 47 |
| Furosemide | Furosemide | 123 | 48 |
| Metoprolol Tartrate | Metoprolol Tartrate | 121 | 48 |
| Fluticasone Propionate | Fluticasone Propionate | 120 | 52 |
| Tamsulosin Hcl | Tamsulosin Hcl | 113 | 43 |
| Azithromycin | Azithromycin | 111 | 91 |
| Citalopram Hbr | Citalopram Hydrobromide | 102 | 33 |
| Alendronate Sodium | Alendronate Sodium | 99 | 36 |
| Simvastatin | Simvastatin | 99 | 30 |
| Clopidogrel | Clopidogrel Bisulfate | 97 | 27 |
| Tizanidine Hcl | Tizanidine Hcl | 97 | 31 |
| Meloxicam | Meloxicam | 93 | 34 |
| Allopurinol | Allopurinol | 85 | 28 |
| Ozempic | Semaglutide | 81 | 13 |
| Metoprolol Succinate | Metoprolol Succinate | 76 | 31 |
| Naproxen | Naproxen | 76 | 23 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 74 | 37 |
| Glipizide | Glipizide | 73 | 21 |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 73 | 32 |
| Ezetimibe | Ezetimibe | 70 | 23 |
| Eliquis | Apixaban | 68 | 20 |
| Potassium Chloride | Potassium Chloride | 67 | 26 |
| Famotidine | Famotidine | 65 | 24 |
| Methylprednisolone | Methylprednisolone | 64 | 50 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 60 | 52 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 56 | 48 |
| Diclofenac Sodium | Diclofenac Sodium | 56 | 27 |
| Fluoxetine Hcl | Fluoxetine Hcl | 55 | 12 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 51 | 15 |
| Clonidine Hcl | Clonidine Hcl | 50 | 14 |
| Montelukast Sodium | Montelukast Sodium | 48 | 17 |
| Pregabalin | Pregabalin | 48 | 15 |
| Ultra-Fine Short Pen Needle | Pen Needle, Diabetic | 48 | 15 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 47 | 13 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 44 | 15 |
| Tradjenta | Linagliptin | 43 | suppressed |
| Nystatin | Nystatin | 42 | 27 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 42 | 13 |
| Baclofen | Baclofen | 41 | 14 |
| Farxiga | Dapagliflozin Propanediol | 40 | 12 |
| Fenofibrate | Fenofibrate | 39 | 11 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 39 | 13 |
| Hydralazine Hcl | Hydralazine Hcl | 36 | suppressed |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 36 | 14 |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 35 | 24 |
| Pravastatin Sodium | Pravastatin Sodium | 35 | 13 |
| Quetiapine Fumarate | Quetiapine Fumarate | 35 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 34 | 32 |
| Xarelto | Rivaroxaban | 33 | 16 |
| Prednisone | Prednisone | 31 | 24 |
| Mupirocin | Mupirocin | 30 | 19 |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 30 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Sertraline Hcl | Sertraline Hcl | 28 | 11 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 27 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 27 | suppressed |
| Duloxetine Hcl | Duloxetine Hcl | 26 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 26 | suppressed |
| Rybelsus | Semaglutide | 26 | 13 |
| Meclizine Hcl | Meclizine Hcl | 25 | 18 |
| Pioglitazone Hcl | Pioglitazone Hcl | 25 | suppressed |
| Symbicort | Budesonide/Formoterol Fumarate | 25 | suppressed |
| Levemir Flexpen | Insulin Detemir | 24 | suppressed |
| Linzess | Linaclotide | 24 | suppressed |
| Spironolactone | Spironolactone | 24 | suppressed |
| Finasteride | Finasteride | 23 | suppressed |
| Fluconazole | Fluconazole | 23 | 20 |
| Single Use Swab | Alcohol Antiseptic Pads | 23 | suppressed |
| Trulicity | Dulaglutide | 23 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 22 | 14 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 22 | suppressed |
| Levofloxacin | Levofloxacin | 22 | 19 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Januvia | Sitagliptin Phosphate | 21 | suppressed |
| Acyclovir | Acyclovir | 19 | suppressed |
| Ammonium Lactate | Ammonium Lactate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 18 | suppressed |
| Ventolin Hfa | Albuterol Sulfate | 18 | 12 |
| Breyna | Budesonide/Formoterol Fumarate | 17 | suppressed |
| Humulin 70-30 | Insulin Nph Hum/Reg Insulin Hm | 17 | suppressed |
| Mirtazapine | Mirtazapine | 17 | suppressed |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 17 | 15 |
| Propranolol Hcl | Propranolol Hcl | 17 | suppressed |
| Alcohol Swabs | Alcohol Antiseptic Pads | 16 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 16 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 15 | suppressed |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 15 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 15 | suppressed |
| Levetiracetam | Levetiracetam | 14 | suppressed |
| Myrbetriq | Mirabegron | 14 | suppressed |
| Sucralfate | Sucralfate | 14 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 14 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 13 | suppressed |
| Ketoconazole | Ketoconazole | 13 | suppressed |
| Veo Insulin Syringe | Syringe And Needle,insulin,1ml | 13 | suppressed |
| Advocate Pen Needles | Pen Needle, Diabetic | 12 | suppressed |
| Atenolol | Atenolol | 11 | suppressed |
| Insulin Syringe | Syringe And Needle,insulin,1ml | 11 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 11 | suppressed |
| Nifedipine Er | Nifedipine | 11 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 11 | suppressed |
| Verapamil Er | Verapamil Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $316.64 · 17 records | PFIZER INC. | ABRYSVO, AIRSUPRA, BEYFORTUS, CAPVAXIVE, COMIRNATY, Cologuard Collection Kit, DAYBUE, Doc Band, EDARBI, ENFLONSIA, FLUZONE QUADRIVALENT NORTHERN HEMISPHERE, GARDASIL 9, JARDIANCE, Kerendia, Korlym, MENQUADFI, PENBRAYA, PREVNAR 20, TRUMENBA, TZIELD, Wegovy | 7 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Jardiance play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error